SIGA Technologies has gained the Japanese regulatory approval for TEPOXX (tecovirimat) for the treatment of smallpox, mpox and cowpox.

Nepal has confirmed two additional cases of mpox among migrant workers, according to health authorities on Friday. With the ...

As the world continues to recover from the devastating effects of the Covid-19 pandemic, experts are now warning about ...

These two mpox cases point to the hazardous conditions and risky behaviours of Nepali migrant workers. Several international ...

Surveillance data from the Centers for Disease Control and Prevention (CDC) indicate a spike in norovirus outbreaks in the ...

The survey of adults in 6 African nations finds 33% are reluctant to receive the mpox vaccine and 39% of parents are ...

On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment ...

Childhood vaccination rates are on the decline at a time when Robert F. Kennedy Jr. could lead the Health and Human Services ...

TPOXX is approved in the U.S. and Canada for the treatment of smallpox. In the European Union and United Kingdom, marketed as Tecovirimat-SIGA, it is approved for the treatment of smallpox, mpox, ...

SIGA Technologies (SIGA) stock gains as Japan approves antiviral Tepoxx as a treatment for orthopoxviruses including mpox.